Context Therapeutics Inc. (CNTX) Stock

Context Therapeutics Inc. (CNTX) is a Healthcare stock trading at $0.60 (as of 2026-07-31), with a market capitalization of $54.75M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies for women in the United States. Its pipeline includes onapristone extended release (ONA-XR) and CLDN6xCD3, an anti-CD3 x anti-claudin 6 bispecific antibody, and it also has a collaboration and licensing arrangement with Integral Molecular for an anti-claudin 6 bispecific monoclonal antibody in gynecologic cancer.

Understand Context Therapeutics Inc.: how it makes money

Context Therapeutics develops cancer therapies for women, including ONA-XR (an extended-release progesterone receptor antagonist) and CLDN6xCD3 (a bispecific antibody designed to redirect T-cells to claudin 6 expressing cells), and it would primarily make money if these candidates successfully reach commercialization, potentially supported by partnerships and later product sales.

The profit model is pipeline driven, the economics hinge on whether clinical-stage programs like ONA-XR and CLDN6xCD3 demonstrate enough efficacy and safety to advance into and through commercialization.

Business quality (Weak): High scientific specificity, but the business is inherently binary and outcome dependent because there is no segment revenue breakdown and the latest reported quarter shows no revenue.

Bull case

  • Targeted mechanism in cancer: ONA-XR is a potent and selective progesterone receptor antagonist linked to resistance for several classes of cancer therapeutics, including anti-estrogen therapies across female hormone-dependent cancers.
  • T-cell redirection strategy: CLDN6xCD3 is designed to redirect T-cell-mediated lysis toward cells associated with the anti-CD3 and anti-claudin 6 antigen combination.

Bear case

  • Clinical-stage outcome risk: As a clinical-stage biopharmaceutical company, future value depends on trial results for ONA-XR and CLDN6xCD3, which are uncertain.
  • No reported revenue and heavy operating losses: The latest reported quarter shows revenue of 0.0B and an operating margin of -1796.4%, which underscores reliance on continued development spending before any product revenue exists.
Valuation — source: SEC EDGAR (first-party)
Price$0.60
Market Cap$54.75M
Price / Book1.43
Price / Sales23.88
FCF Yield-107.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$3.38M
Net Margin-1069.2%
Revenue Growth (YoY)5.6%
EPS Growth (YoY)-17.4%
FCF Growth (YoY)81.4%
Financial Health — source: SEC EDGAR
Altman Z-Score0.61 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderMPM BIOIMPACT LLC ($27.98M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMartin A. Lehr
Employees12
CountryUS
IPO Date2021-10-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Talphera, Inc. (TLPH)
  • RenovoRx, Inc. (RNXT)
  • Stablecoin Development Corp (SDEV)
  • Clene Inc. (CLNN)
  • Xilio Therapeutics, Inc. (XLO)
  • Impact BioMedical Inc. (IBO)
  • TransCode Therapeutics, Inc. (RNAZ)
  • Hyperion DeFi, Inc. (HYPD)
CNTX earnings history · CNTX institutional & insider holders · CNTX KPIs & operating metrics · CNTX financials · CNTX investor presentations & press releases · CNTX SEC filings · CNTX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-31.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.